Saxenda side effects and stopping GLP-1s: what the data says

What did @fit2fat2fitagain actually say?

The creator says she and her partner "Huppy" both stopped taking Saxenda (liraglutide) after noticing significant mood changes. Huppy, who has a history of depression and anxiety since his teens, experienced mood declines around weeks five to six. She describes it as "a really, really rough time for a few weeks" before connecting it to the medication. She also reports two months of unusually heavy menstrual bleeding she'd never experienced before. Both stopped the medication about a month ago and report major wellbeing improvements.

She's careful to note this isn't universal: "This isn't for everybody, it's not going to affect everybody the exact same way." That caveat matters. This is a personal experience video, not a medical recommendation. But with 88K views, the framing carries weight whether she intends it to or not.

Does the science back this up?

On mood and depression, the evidence is genuinely complicated. There's no clean answer here, and anyone telling you otherwise hasn't read the literature carefully.

Liraglutide's prescribing information does list depression and suicidal ideation as potential risks requiring monitoring. The FDA added warnings about mood-related adverse events to GLP-1 receptor agonist labels after post-market surveillance flagged signals. A 2023 pharmacovigilance analysis by Rubino et al. in Nature Medicine reviewed WHO adverse event data and found that semaglutide was associated with lower rates of suicidal ideation compared to controls, which generated headlines. But liraglutide is a different molecule with different receptor binding profiles, and the same signal wasn't necessarily replicated across all GLP-1s. Pre-existing psychiatric history, as Huppy has, changes the risk calculus significantly.

On heavy menstrual bleeding, the evidence is thinner. There are case reports and emerging patient-reported data linking GLP-1 use to menstrual cycle changes, but no large randomized controlled trials have specifically isolated liraglutide as a cause of menorrhagia. The mechanism isn't well understood. Rapid weight loss itself can alter hormonal cycles, which complicates attribution.

What did they get wrong (or right)?

They got several things right. Flagging mood changes in someone with a documented psychiatric history as a possible medication side effect is clinically reasonable. The prescribing doctors were apparently informed of Huppy's depression and anxiety before starting, which is the correct process. Stopping a medication under medical supervision when adverse effects appear is also correct.

The heavy bleeding claim is trickier. She frames it as definitely Saxenda-related: "for the two months, it was just like unheard of." That's plausible, but it's also possible that weight changes, stress, or other factors were contributing. The honest answer is she can't know for certain, and neither can we without a controlled observation. She doesn't present it as confirmed, but the implied causation is stronger than the evidence supports.

What's missing is any mention of speaking to a gynecologist or getting hormonal panels checked. Menstrual disruption during weight loss intervention warrants investigation, not just medication cessation.

What should you actually know?

If you have a history of depression, anxiety, or other mood disorders, that's a conversation that needs to happen with your prescribing clinician before starting any GLP-1 medication, not after you notice a decline. The Saxenda label specifically recommends monitoring patients with a history of depression or suicidal ideation. That's not a theoretical warning.

GLP-1 receptors are expressed in the brain, including regions involved in mood regulation. Research is ongoing on whether this is therapeutically useful or a source of adverse effects in vulnerable individuals. A 2022 study by Mansur et al. in Journal of Affective Disorders explored GLP-1 agonists as potential mood modulators, but the bidirectional risk in people with existing psychiatric conditions is not resolved.

On the menstrual side, the FDA's Adverse Event Reporting System has received a growing number of reports about cycle disruption with GLP-1 use, but this hasn't translated into strong label warnings yet. If you experience significant menstrual changes on any GLP-1, report it to your doctor and ask about hormonal evaluation.

The creator's recommendation to stop if something doesn't feel right is reasonable advice in plain terms, but always do that in consultation with your prescriber, not unilaterally.